Crossmark

Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines

Crossref DOI link: https://doi.org/10.1186/s12936-018-2555-3

Published Online: 2018-11-06

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Berman, Jonathan

Brown, Tracey

Dow, Geoffrey

Toovey, Stephen
License Information

Text and Data Mining valid from 2018-11-06
More Information

Article History

Received: 22 March 2018

Accepted: 27 October 2018

First Online: 6 November 2018